Together, we can end viral hepatitis.

We are the only grant-making organization dedicated exclusively to the mission of ending viral hepatitis.

By funding a variety of the most effective activities, EndHep2030 intends to overcome the barriers that prevent countries from properly addressing viral hepatitis — a pandemic that will kill 1.4 million people this year — as a global public health threat.

EndHep2030’s catalytic funding will be the spark that sets a historic effort in motion. MORE

In the News

09.26.2019

Hepatitis elimination discussed at the Global Fund Replenishment Conference.

As part of the Global Fund Replenishment Conference, leading experts discussed how a more collaborative approach toward HIV and hepatitis elimination can help better utilize health resources and achieve optimal health outcomes.

Viral hepatitis is a leading cause of death globally, killing more than 1.4 million people each year. By 2040, deaths from hepatitis will exceed that of HIV, TB and malaria combined if the status quo persists.

During the session, it was concluded that effective global health programs should utilize a people-centered, rather than disease-centered approach and that elimination of viral hepatitis should be part of Universal Health Coverage. Currently, testing and treatment for hepatitis is affordable and high impact. Recommendations to the Global Fund included: supporting elimination goals for HCV and HBV among people with TB and people living with HIV; ensuring that services funded by the Global Fund provide prevention and treatment for HIV, TB and hepatitis; and utilizing Global Fund procurement systems to reduce the commodity price for hepatitis diagnostics and treatment.

2030

Highly Motivated

The boys of Baruun-Urt have a genius for mischief, a deep love for mud of any kind, and an 85% chance of being born with viral hepatitis.

See how catalytic funding of select programs is making a difference in Mongolia. >>

More than 10% of Mongolia’s three million people are living with chronic hepatitis infection. The chances of a mother with viral hepatitis giving birth to an infected baby who develops life-long infection can be as high as 85%.

Fortunately, though heavily burdened by the disease, Mongolia has become a champion in the fight against it. In the first year of its Healthy Liver Program, more than 350,000 people were tested, and over 70% of those diagnosed with hepatitis were provided with treatment that is life-saving and prevents infection to others.

The means to prevent and cure the disease exist now. All we need is the will — and commitment — to make it happen.

Donors